

General information about company		
Script code*	506235	
NSE Symbol*	ALEMBICLTD	
MSEI Symbol*	NOTLISTED	
ISIN*	INE426A01027	
Name of company	Alembic Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2025	
Date of end of financial year	31-03-2026	
Date of board meeting when results were approved	10-11-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	31-10-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Second quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Unaudited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited	
Segment Reporting	Multi segment	
Description of single segment		
Start date and time of board meeting	10-11-2025 16:00	
End date and time of board meeting	10-11-2025 16:45	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half/year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bank/Non-Banking Finance Company are at the terms uniformly applicable/offered to all stakeholders/public.	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 25 of SEBI LODR) has been uploaded on the website of the Company?	Yes	
Latest Date on which RPT policy is updated	07-02-2025	
Indicate Company website link for updated RPT policy of the Company	https://alembiclimited.com/policy/Related-Party-Transaction-Policy.pdf	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No	
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	Not Applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-06-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	5403.68	10192.26
	Other income	6479.84	6825.69
	Total income	11883.52	17017.95
2	Expenses		
(a)	Cost of materials consumed	252.6	598.06
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	40.34	214.55
(d)	Employee benefit expense	755.48	1538.14
(e)	Finance costs	40.32	82.56
(f)	Depreciation, depletion and amortisation expense	272.04	541.71
(g)	Other Expenses		
1	Cost of Construction	1290.76	2300.72
2	Other Expenses	812.83	1431.36
	Total other expenses	2103.59	3732.08
	Total expenses	3464.37	6707.1
3	Total profit before exceptional items and tax	8419.15	10310.85
4	Exceptional items	0	0
5	Total profit before tax	8419.15	10310.85
6	Tax expense		
7	Current tax	1060.11	1270.29
8	Deferred tax	-234	-234.45
9	Total tax expenses	856.11	1035.84
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	7563.04	9275.01
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	7563.04	9275.01
17	Other comprehensive income net of taxes	12463.55	12887.82
18	Total Comprehensive Income for the period	20026.59	22162.83
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	5135.64	5135.64
	Face value of equity share capital	2	2
22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	2.95	3.61
	Diluted earnings (loss) per share from continuing operations	2.95	3.61
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	2.95	3.61
	Diluted earnings (loss) per share from continuing and discontinued operations	2.95	3.61
24	Debt equity ratio		Textual Information(1)
25	Debt service coverage ratio		Textual Information(2)
26	Interest service coverage ratio		Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)	

Text Block	
Textual Information(4)	1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2. The previous quarter/s / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. 3. Figures rounded off to the nearest decimal.

Statement of Asset and Liabilities		
Particulars	Half Year ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Assets		
1 Non-current assets		
Property, plant and equipment		13456.47
Capital work-in-progress		21.75
Investment property		28940.79
Goodwill		0
Other intangible assets		0
Intangible assets under development		0
Biological assets other than bearer plants		0
Investments accounted for using equity method		0
Non-current financial assets		
Non-current investments		51554.53
Trade receivables, non-current		0
Loans, non-current		0
Other non-current financial assets		655.14
Total non-current financial assets		52209.67
Deferred tax assets (net)		0
Other non-current assets		3500
Total non-current assets		98128.68
2 Current assets		
Inventories		9203.17
Current financial asset		
Current investments		7606.04
Trade receivables, current		2965.36
Cash and cash equivalents		103.4
Bank balance other than cash and cash equivalents		200.61
Loans, current		0
Other current financial assets		292.85
Total current financial assets		11168.26
Current tax assets (net)		0
Other current assets		1223.88
Total current assets		21595.31
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debt balances and related deferred tax Assets		0
Total assets		119723.99
Total current assets	21595.31	
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debt balances and related deferred tax Assets		0
Total assets	119723.99	
Equity and liabilities		
1 Equity		
Equity attributable to owners of parent		
Equity share capital		5135.64
Other equity		96183.56
Total equity attributable to owners of parent	101319.2	
Non controlling interest		
Total equity	101319.2	
2 Liabilities		
Non-current liabilities		
Non-current financial liabilities		
Borrowings, non-current		857.04
Trade Payables, non-current		
(A) Total outstanding dues of micro enterprises and small enterprises		0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		0
Total Trade payable	0	
Other non-current financial liabilities		726.11
Total non-current financial liabilities	1583.15	
Provisions, non-current		325.9
Deferred tax liabilities (net)		4745.73
Deferred government grants, Non-current		0
Other non-current liabilities		0
Total non-current liabilities	6654.78	
Current liabilities		
Current financial liabilities		
Borrowings, current		401.23
Trade Payables, current		
(A) Total outstanding dues of micro enterprises and small enterprises		568.56
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		2236.36
Total Trade payable	2804.92	
Other current financial liabilities		714.29
Total current financial liabilities	3920.44	
Other current liabilities		4733.97
Provisions, current		2160.84
Current tax liabilities (Net)		934.76
Deferred government grants, Current		0
Total current liabilities	11750.01	
3 Liabilities directly associated with assets in disposal group classified as held for sale		0
4 Regulatory deferral account credit balances and related deferred tax liability		0
Total liabilities	18404.79	

	Total equity and liabilities	119723.99
Disclosure of notes on assets and liabilities	Textual information(1)	

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-01-2025	01-01-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
1 Active Pharmaceutical Ingredients Business	1030.48	2325.89
2 Real Estate Business	4373.2	7866.37
Total Segment Revenue	5403.68	10192.26
Less: Inter segment revenue	0	0
Revenue from operations	5403.68	10192.26
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
1 Active Pharmaceutical Ingredients Business	195.06	467.99
2 Real Estate Business	1966.16	3436.17
Total Profit before tax	2161.22	3924.16
i. Finance cost	40.32	82.56
ii. Other Unallocable Expenditure net off Unallocable income	-6298.26	-6469.25
Profit before tax	8419.16	10310.85
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
1 Active Pharmaceutical Ingredients Business	18430.34	18430.34
2 Real Estate Business	47428.02	47428.02
Total Segment Asset	65858.36	65858.36
Un-allocable Assets	53865.62	53865.62
Net Segment Asset	119723.98	119723.98
4 Segment Liabilities		
Segment Liabilities		
1 Active Pharmaceutical Ingredients Business	3254.78	3254.78
2 Real Estate Business	9469.52	9469.52
Total Segment Liabilities	12724.3	12724.3
Un-allocable Liabilities	5680.48	5680.48
Net Segment Liabilities	18404.78	18404.78
Disclosure of notes on segments		

Other Comprehensive Income		
Date of start of reporting period		01-07-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
Other comprehensive income (Abstract)		
1	Amount of items that will not be reclassified to profit and loss	
1	Amount of items that will not be reclassified to profit and loss	14539.01
	Total Amount of items that will not be reclassified to profit and loss	15034.07
2	Income tax relating to items that will not be reclassified to profit or loss	2075.46
3	Amount of items that will be reclassified to profit and loss	
	Total Amount of items that will be reclassified to profit and loss	
4	Income tax relating to items that will be reclassified to profit or loss	0.00
5	Total Other comprehensive income	12463.55

Cash flow statement, indirect		
Particulars	Half Year ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
Part I Blue color marked fields are non-mandatory.		
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	10310.85
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	82.56
	Adjustments for decrease (increase) in inventories	735.53
	Adjustments for decrease (increase) in trade receivables, current	-176.36
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-14.23
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	146.8
	Adjustments for other financial assets, current	-25.8
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	47.06
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	480.89
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	541.71
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	48.39
	Adjustments for provisions, non-current	9.28
	Adjustments for other financial liabilities, current	72.3
	Adjustments for other financial liabilities, non-current	-34.89
	Adjustments for unrealised foreign exchange losses/gains	0
	Adjustments for dividend income	6288.3
	Adjustments for interest income	75.05
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	-70.03
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-4398.76
	Net cash flows from (used in) operations	5912.09
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	1015.92
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	4896.17
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	8405.71
	Other cash payments to acquire equity or debt instruments of other entities	11062.41
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	57.15
	Proceeds from sales of investment property	0
	Purchase of investment property	2263.55
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	6288.3
	Interest received	75.05
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-34.74
	Net cash flows from (used in) investing activities	1381.21
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0

	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	186.46
	Payments of lease liabilities	0
	Dividends paid	6128.01
	Interest paid	82.56
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-6397.03
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-149.65
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	-149.65
	Cash and cash equivalents cash flow statement at beginning of period	253.04
	Cash and cash equivalents cash flow statement at end of period	103.39

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity/ subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period		In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes		
1	ALEMBIC LIMITED	AABCA7950P	NIRAYU PRIVATE LIMITED	AAACN7427K	HOLDING	Any other transaction	SECURITY DEPOSIT RECEIVED	0	No Additional Remarks			0	0.12	0.12											There were no transactions during the period.
2	ALEMBIC LIMITED	AABCA7950P	NIRAYU PRIVATE LIMITED	AAACN7427K	HOLDING	Sale of goods or services		0.28	No Additional Remarks			0.28	0	0											
3	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	SECURITY DEPOSIT RECEIVED	106.19	No Additional Remarks			106.19	510.83	617.02											
4	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Sale of goods or services		1730.57	No Additional Remarks			1730.57	0	0											
5	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	REIMBURSEMENT OF EXPENSES PAID	16.66	No Additional Remarks			16.66	0	0											
6	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Any other transaction	REIMBURSEMENT OF EXPENSES RECEIVED	241.46	No Additional Remarks			241.46	0	0											
7	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CITY LIMITED	AABCA9411F	SUBSIDIARY	Investment		0	No Additional Remarks			0	10.07	10.07					Investment	0.00%	NA	Unsecured	NA		There were no transactions during the period.
8	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA591M	ASSOCIATE	Investment		0	No Additional Remarks			0	8665.07	8665.07					Investment	0.00%	NA	Unsecured	NA		There were no transactions during the period.
9	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA591M	ASSOCIATE	Any other transaction	SECURITY DEPOSIT RECEIVED	0	No Additional Remarks			0	329.5	329.5											There were no transactions during the period.
10	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA591M	ASSOCIATE	Sale of goods or services		2763.89	No Additional Remarks			2763.89	616.22	343.86											
11	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA591M	ASSOCIATE	Purchase of goods or services		13.85	No Additional Remarks			13.85	0	13.63											
12	ALEMBIC LIMITED	AABCA7950P	ALEMBIC PHARMACEUTICALS LIMITED	AAICA591M	ASSOCIATE	Any other transaction	REIMBURSEMENT OF EXPENSES RECEIVED	327.43	No Additional Remarks			327.43	0	0											
13	ALEMBIC LIMITED	AABCA7950P	PAUSHAK LIMITED	AAACD906G	PROMOTER GROUP	Investment		0	No Additional Remarks			0	26550.45	41602.18					Investment	0.00%	NA	Unsecured	NA		1. There are no transactions during the period. 2. Change in opening and closing values reflects variation in market price (net of necessary tax adjustments) of shares of the listed entity.
14	ALEMBIC LIMITED	AABCA7950P	PAUSHAK LIMITED	AAACD906G	PROMOTER GROUP	Sale of goods or services		42.62	No Additional Remarks			42.62	0	0											
15	ALEMBIC LIMITED	AABCA7950P	PAUSHAK LIMITED	AAACD906G	PROMOTER GROUP	Purchase of goods or services		25.54	No Additional Remarks			25.54	0	0											
16	ALEMBIC LIMITED	AABCA7950P	SHRENO LIMITED	AABCA7953Q	PROMOTER GROUP	Sale of goods or services		308.68	No Additional Remarks			308.68	88.07	51.17											
17	ALEMBIC LIMITED	AABCA7950P	SHRENO PUBLICATIONS LIMITED	AAICA4386B	PROMOTER GROUP	Sale of goods or services		46.02	No Additional Remarks			46.02	0	0											
18	ALEMBIC LIMITED	AABCA7950P	SHRENO ENGINEERING LIMITED	ABGCS4837F	PROMOTER GROUP	Any other transaction	SECURITY DEPOSIT RECEIVED	0	No Additional Remarks			0	0.12	0.12											There were no transactions during the period.
19	ALEMBIC LIMITED	AABCA7950P	SHRENO ENGINEERING LIMITED	ABGCS4837F	PROMOTER GROUP	Sale of goods or services		0.28	No Additional Remarks			0.28	0	0											
20	ALEMBIC LIMITED	AABCA7950P	SHRENO ENGINEERING LIMITED	ABGCS4837F	PROMOTER GROUP	Purchase of goods or services		0.18	No Additional Remarks			0.18	0	0.18											
21	ALEMBIC LIMITED	AABCA7950P	RAKSHAK SERVICES PRIVATE LIMITED	AABCR0028H	PROMOTER GROUP	Purchase of goods or services		3.83	No Additional Remarks			3.83	0.81	0											
22	ALEMBIC LIMITED	AABCA7950P	ALEMBIC CSR FOUNDATION	AAETA7647M	OTHER RELATED PARTY	Any other transaction	CSR CONTRIBUTION	56.08	No Additional Remarks			56.08	0	0											
23	ALEMBIC LIMITED	AABCA7950P	ALEMBIC LIMITED PROVIDENT FUND	AABTT1558R	OTHER RELATED PARTY	Any other transaction	POST EMPLOYMENT BENEFITS PLAN	117.53	No Additional Remarks			117.53	0	0											
24	ALEMBIC LIMITED	AABCA7950P	BHAILAL AMIN GENERAL HOSPITAL	AAATB1585B	PROMOTER GROUP	Any other transaction	SECURITY DEPOSIT RECEIVED	0	No Additional Remarks			0	2.22	2.22											There were no transactions during the period.
25	ALEMBIC LIMITED	AABCA7950P	BHAILAL AMIN GENERAL HOSPITAL	AAATB1585B	PROMOTER GROUP	Sale of goods or services		5.85	No Additional Remarks			5.85	0	0											
26	ALEMBIC LIMITED	AABCA7950P	MALIKA AMIN	ABMPA5730G	PROMOTERS	Remuneration		72	No Additional Remarks			72	0	0											
27	ALEMBIC LIMITED	AABCA7950P	ALCHEMY CITY WEST PROJECT MANAGEMENT ASSOCIATION	AAVCA4394E	OTHER RELATED PARTY	Any other transaction	SECURITY DEPOSIT RECEIVED	0	No Additional Remarks			0	0.12	0.12											There were no transactions during the period.

[illegible]

[illegible]